The Pharmaceutical Research Center (PRC) (previously named Investigational Drug Services/IDS) ensures the safe and ethical provision of investigational/study drugs to research subjects enrolled in clinical drug trials within the UWCCC. It ensures that drug research protocols proceed optimally through the University of Wisconsin Hospital and Clinics'(UWHC) medication use system and in accordance with all federal, state, institutional and sponsor regulations: The services are continually refined and expanded to meet the evolving needs of the UWCCC clinical research. While the PRC program at UW/UWHC supports all investigators conducting clinical drug research, its relationship with the UWCCC is unique in its level of commitment, the breadth and depth of services provided, and expertise in handling biohazardous and gene therapy products. The PRC provides detailed protocol review and feasibility assessment within the confines of an academic medical center. It ensures full compliance with federal, state, sponsor and institutional requirements through activities such as: establishment of drug handlihg/distribution/preparation/destruction procedures;creation of investigational drug monographs for health care providers;education of health care staff regarding protocol procedures;creation of preprinted physician orders and prescriptions;drug inventory management and accountability;drug preparation and/or oversight;quality assurance audits;and protocol amendment management. It operates satellite pharmacy locations, optimizing ability to extend clinical research into the community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-36
Application #
7809600
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
36
Fiscal Year
2009
Total Cost
$97,959
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Xu, Cheng; Chen, Feng; Valdovinos, Hector F et al. (2018) Bacteria-like mesoporous silica-coated gold nanorods for positron emission tomography and photoacoustic imaging-guided chemo-photothermal combined therapy. Biomaterials 165:56-65
Wargowski, Ellen; Johnson, Laura E; Eickhoff, Jens C et al. (2018) Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine. J Immunother Cancer 6:21
Bednarz, Bryan; Grudzinski, Joseph; Marsh, Ian et al. (2018) Murine-specific Internal Dosimetry for Preclinical Investigations of Imaging and Therapeutic Agents. Health Phys 114:450-459
Romero-Masters, James C; Ohashi, Makoto; Djavadian, Reza et al. (2018) An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model. PLoS Pathog 14:e1007221
van den Broek, Jeroen J; van Ravesteyn, Nicolien T; Mandelblatt, Jeanne S et al. (2018) Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49. Med Decis Making 38:140S-150S
Lu, Zhanping; Hong, Courtney C; Kong, Guangyao et al. (2018) Polycomb Group Protein YY1 Is an Essential Regulator of Hematopoietic Stem Cell Quiescence. Cell Rep 22:1545-1559
Shea, Michael P; O'Leary, Kathleen A; Fakhraldeen, Saja A et al. (2018) Antiestrogen Therapy Increases Plasticity and Cancer Stemness of Prolactin-Induced ER?+ Mammary Carcinomas. Cancer Res 78:1672-1684
Schrager, Sarina; Burnside, Elizabeth (2018) Breast Cancer Screening in Primary Care: A Call for Development and Validation of Patient-Oriented Shared Decision-Making Tools. J Womens Health (Larchmt) :
Ehlerding, Emily B; Grodzinski, Piotr; Cai, Weibo et al. (2018) Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics. ACS Nano 12:2106-2121
Liu, Bai; Jones, Monica; Kong, Lin et al. (2018) Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models. Cytokine 107:105-112

Showing the most recent 10 out of 1528 publications